Alkermes

ALKS

Market cap $4.98B

GES, NESR and ALKS made it to the Zacks Rank #1 (Strong Buy) value stocks list on Jan.14, 2026.

Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton's Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline.

Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patients with NT1. Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in developm.

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth.

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?